Table 3.
Clinical demographics of Cohort 2 (35 patients).
| Background | Complete blood count# | ||
| Sex (M/F) | 22/13 | Red blood cell (× 104/µL) (n = 35) | 436.6 ± 10.94 |
| Age (years old) (median, range) | 42 (17–90) | Hemoglobin (g/dL) (n = 35) | 11.92 ± 0.3198 |
| Height (cm)*, # (mean, range) | 165.0 ± 1.4 | Hematocrit (%) (n = 35) | 37.12 ± 0.8463 |
| Body weight (kg)*, # (mean, range) | 57.7 ± 1.9 | MCV (fL) (n = 35) | 85.46 ± 1.230 |
| Body mass index*, # (mean, range) | 21.0 ± 0.6 | MCH (pg) (n = 35) | 27.57 ± 0.5806 |
| UC disease duration (years) (median, range) | 7.2 (0.6–38.0) | MCHC (g/dL) (n = 35) | 31.86 ± 0.2824 |
| UC disease type (total colitis/left-sided colitis) | 26/9 | White blood cell (× 103/µL) (n = 35) | 8.980 ± 0.4852 |
| Treatment history for UC | Neutrophil (%) (n = 35) | 68.74 ± 2.414 | |
| 5-ASA (+ /−) | 35/0 | Eosinophil (%) (n = 35) | 2.411 ± 0.4785 |
| Azathioprine (+ /−) | 16/19 | Basophil (%) (n = 35) | 0.5057 ± 0.07658 |
| Prednisolone (+ /−) | 34/1 | Monocyte (%) (n = 35) | 5.783 ± 0.3977 |
| Anti TNF-alpha agent (+ /−) | 20/15 | Lymphocyte (%) (n = 35) | 22.13 ± 2.096 |
| Tofacitinib (+ /−) | 6/29 | Platelet (× 104/µL) (n = 35) | 37.60 ± 1.796 |
| Tacrolimus (+ /−) | 9/26 | Blood chemistry# | |
| Granulocyte and monocyte apheresis (+ /−) | 13/22 | BUN (mg/dL) (n = 35) | 11.44 ± 0.6232 |
| Concomitant treatment for UC | Creatinine (mg/dL) (n = 35) | 0.7643 ± 0.02761 | |
| 5-ASA (+ /−) | 29/6 | eGFR (mL/min) (n = 34) | 82.91 ± 2.631 |
| Azathioprine (+ /−) | 4/31 | Total bilirubin (mg/dL) (n = 35) | 0.5171 ± 0.03678 |
| Prednisolone (+ /−) | 11/24 | AST (IU/L) (n = 35) | 16.71 ± 1.498 |
| Clinical activity of UC | ALT (IU/L) (n = 35) | 15.37 ± 2.743 | |
| Lichtiger index (median, range) | 7 (5–12) | GGT (IU/L) (n = 28) | 28.57 ± 7.053 |
| Partial Mayo score (median, range) | 5 (2–8) | Total protein (g/dL) (n = 35) | 7.303 ± 0.1118 |
| Endoscopic activity of UC (n = 31) | Albumin (g/dL) (n = 35) | 3.689 ± 0.08419 | |
| Mayo endoscopic subscore (median, range) | 2.5 (0–3) | Globulin (g/dL) (n = 35) | 3.614 ± 0.07758 |
| UCEIS | 5.5 (0–7) | Total cholesterol (mg/dL) (n = 33) | 177.3 ± 6.781 |
| UCEIS-V | 2 (0–2) | CRP (mg/dL) (n = 35) | 1.091 ± 0.2146 |
| UCEIS-E | 2 (0–3) | Achievement of SFCR at week 22 (yes/no) | 13/22 |
| UCEIS-B | 1.5 (0–3) | ||
*Height and body mass index were not measured in three subjects.
#The results of blood tests are described as the mean ± SEM.